Mainz Biomed, a German cancer diagnostic firm, has partnered with Liquid Biosciences to use their artificial intelligence platform, Emerge, for analyzing clinical study results of its colorectal cancer test, ColoAlert. This collaboration will focus on analyzing data from Mainz’s EAArly Detect study in the US and the upcoming ReconAAsense trial for FDA premarket approval. The aim is to develop a fixed machine learning-based algorithm with Emerge, enhancing ColoAlert’s capabilities and paving the way for a next-generation colorectal cancer screening tool. ColoAlert, a noninvasive test that detects tumor DNA using PCR technology, is already available in multiple European countries.
Keep Reading
Add A Comment